Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma

Gynecologic Oncology

Volumn 90, Issue 2, 2003, Pages 378-381

  Gemignani, Mary L ^a   Schlaerth, Alan C ^a   Bogomolniy, Faina ^a   Barakat, Richard R ^a   Lin, Oscar ^a   Soslow, Robert ^a   Venkatraman, Ennapandam ^a   Boyd, Jeff ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRAF; K RAS; Mucinous; Oncogene; Ovarian cancer

Indexed keywords

DNA;

ARTICLE; CANCER STAGING; CELL TYPE; CODON; CONTROLLED STUDY; DNA ISOLATION; ENDOMETRIOID CARCINOMA; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MEDICAL RECORD; MUCINOUS CARCINOMA; MUTATION RATE; ONCOGENE; ONCOGENE BRAF; ONCOGENE K RAS; OVARY CARCINOMA; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0042624835     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00264-6     Document Type: Article

References (27)

1. Bos J.L. ras oncogenes in human cancer a review . Cancer Res. 49:1989;4682-4689.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
3. Boyd J., Hamilton T.C., Berchuck A. Oncogenes and tumor-suppressor genes. Hoskins W.J., Perez C.A., Young R.C. Principles and practice of gynecologic oncology. 3rd ed:2000;103-128 Lippincott Williams & Wilkins, Philadelphia.
4. Enomoto T., Weghorst C.M., Inoue M., Tanizawa O., Rice J.M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol. 139:1991;777-785.
5. Teneriello M.G., Ebina M., Linnoila R.I., Henry M., Nash J.D., Park R.C., et al. p53 and Kiras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53:1993;3103-3108.
6. Mok S.C., Bell D.A., Knapp R.C., Fishbaugh P.M., Welch W.R., Muto M.G., et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 53:1993;1489-1492.
7. Chien C.H., Chow S.N. Point mutation of the ras oncogene in human ovarian cancer. DNA Cell Biol. 12:1993;623-627.
8. Ichikawa Y., Nishida M., Suzuki H., Yoshida S., Tsunoda H., Kubo T., et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res. 54:1994;33-35.
9. Fujita M., Enomoto T., Inoue M., Tanizawa O., Ozaki M., Rice J.M., et al. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res. 85:1994;1247-1256.
10. Mandai M., Konishi I., Komatsu T., Mori T., Arao S., Nomura H., et al. Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma correlation with tumour progression and nm23 gene expression . Br J Cancer. 72:1995;691-695.
11. Cuatrecasas M., Villanueva A., Matias-Guiu X., Prat J. K-ras mutations in mucinous ovarian tumors a clinicopathologic and molecular study of 95 cases . Cancer. 79:1997;1581-1586.
12. Cuatrecasas M., Erill N., Musulen E., Costa I., Matias-Guiu X., Prat J. K-ras mutations in nonmucinous ovarian epithelial tumors a molecular analysis and clinicopathologic study of 144 patients . Cancer. 82:1998;1088-1095.
13. Tanimoto H., Mehta K.D., Parmley T.H., Shigemasa K., Parham G.P., Clarke J., et al. Expression of the farnesyltransferase beta-subunit gene in human ovarian carcinoma correlation to K-ras mutation . Gynecol Oncol. 66:1997;308-312.
14. Chenevix-Trench G., Kerr J., Hurst T., Shih Y.C., Purdie D., Bergman L., et al. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms clinicopathological correlations . Genes Chromosomes Cancer. 18:1997;75-83.
15. Scambia G., Masciullo V., Benedetti Panici P., Marone M., Ferrandina G., Todaro N., et al. Prognostic significance of ras/p21 alterations in human ovarian cancer. Br J Cancer. 75:1997;1547-1553.
16. Mandai M., Konishi I., Kuroda H., Komatsu T., Yamamoto S., Nanbu K., et al. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Human Pathol. 29:1998;34-40.
17. Haas C.J., Diebold J., Hirschmann A., Rohrbach H., Lohrs U. In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential. Virchows Arch. 434:1999;117-120.
18. Schuyer M., Henzen-Logmans S.C., van der Burg M.E., Fieret J.H., Derksen C., Look M.P., et al. Genetic alterations in ovarian borderline tumours and ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol. 82:1999;147-150.
19. Caduff R.F., Svoboda-Newman S.M., Ferguson A.W., Johnston C.M., Frank T.S. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol. 23:1999;323-328.
20. Varras M.N., Sourvinos G., Diakomanolis E., Koumantakis E., Flouris G.A., Lekka-Katsouli J., et al. Detection and clinical correlations of ras gene mutations in human ovarian tumors. Oncology. 56:1999;89-96.
21. Suzuki M., Saito S., Saga Y., Ohwada M., Sato I. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas. Cancer Genet Cytogenet. 118:2000;132-135.
22. Garrett A.P., Lee K.R., Colitti C.R., Muto M.G., Berkowitz R.S., Monk S.C. K-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol. 20:2001;244-251.
23. Singer G., Kurman R.J., Chang H.W., Cho S.K., Shih I.-M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 160:2002;1223-1228.
24. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature. 417:2002;949-954.
25. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. RAF/RAS oncogenes and mismatch repair status. Nature. 418:2002;934.
26. Boyd J., Takahashi H., Waggoner S.E., Jones L.A., Hajek R.A., Wharton J.T., et al. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Cancer. 77:1995;507-513.
27. Rhei E., Bogomolniy F., Federici M.G., Maresco D.L., Offit K., Robson M.E., et al. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res. 58:1998;3193-3196.